A confirmed first-line option for CLL

被引：0
|
作者：
Rebecca Kirk
机构：
来源：
Nature Reviews Clinical Oncology | 2011年 / 8卷 / 5期
关键词：
D O I：
10.1038/nrclinonc.2011.38
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：253 / 253
相关论文
共 50 条
  • [31] Evolving pediatric airway management: supraglottic devices as a first-line option?
    Javaudin, Francois
    Le Bastard, Quentin
    EUROPEAN JOURNAL OF EMERGENCY MEDICINE, 2025, 32 (02) : 77 - 78
  • [32] Reply to 'The shift of therapeutic strategy for prolactinomas: surgery as the first-line option'
    Petersenn, Stephan
    Fleseriu, Maria
    Melmed, Shlomo
    NATURE REVIEWS ENDOCRINOLOGY, 2024, 20 (05) : 311 - 311
  • [33] Lithium is still a first-line option in the treatment of patients with bipolar disorder
    不详
    Drugs & Therapy Perspectives, 2010, 26 (3) : 9 - 14
  • [34] Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
    Gentile, Massimo
    Shanafelt, Tait D.
    Mauro, Francesca Romana
    Reda, Gianluigi
    Rossi, Davide
    Laurenti, Luca
    Del Principe, Maria Ilaria
    Cutrona, Giovanna
    Angeletti, Ilaria
    Coscia, Marta
    Herishanu, Yair
    Chiarenza, Annalisa
    Molica, Stefano
    Ciolli, Stefania
    Goldschmidt, Neta
    Angrilli, Francesco
    Giordano, Annamaria
    Rago, Angela
    Bairey, Osnat
    Tripepi, Giovanni
    Chaffee, Kari G.
    Sameer, Parikh A.
    Vigna, Ernesto
    Zirlik, Katja
    Shvidel, Lev
    Innocenti, Idanna
    Recchia, Anna Grazia
    Di Raimondo, Francesco
    Del Poeta, Giovanni
    Cortelezzi, Agostino
    Neri, Antonino
    Ferrarini, Manlio
    Gaidano, Gianluca
    Kay, Neil E.
    Polliack, Aaron
    Foa, Robin
    Morabito, Fortunato
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (05) : 703 - 706
  • [35] First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
    Uprety, Dipesh
    Remon, Jordi
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04)
  • [36] Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
    Spacek, Martin
    Doubek, Michael
    Obrtlikova, Petra
    Novak, Jan
    Trneny, Marek
    Hadrabova, Marketa
    Cmunt, Eduard
    Karban, Josef
    Molinsky, Jan
    Simkovic, Martin
    Mocikova, Heidi
    Smolej, Lukas
    Panovska, Anna
    Mohammadova, Lekaa
    LEUKEMIA & LYMPHOMA, 2017, 58 : 119 - 120
  • [37] EHA 2023: New Results on Ibrutinib in Combination with Venetoclax in the First-line Treatment of CLL
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (10) : 447 - 447
  • [38] Updated CLL Guideline Broad Recommendation of Ibrutinib for all Patients in First-Line Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 419 - 419
  • [39] Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis
    Firwana, Belal
    Sonbol, Mohamad Bassam
    Atrash, Shebli
    Ravilla, Rahul
    Raval, Mihir
    Hao, Lin
    Jethava, Yogesh
    Veeraputhiran, Muthu
    Makhoul, Issam
    Sasapu, Appalanaidu
    BLOOD, 2016, 128 (22)
  • [40] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
12345